SCHEMBL4774787

SCHEMBL4774787

COCCNC(=O)c1ccc(NS(=O)(=O)CCc2cccc(Cl)c2Cl)cc1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.47
KMT2A Q03164 2/20 0.47
MEN1 O00255 1/20 0.47
MAPT P10636 1/20 0.44
AURKA O14965 1/20 0.43
AURKB Q96GD4 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
GLA P06280 1/20 0.43
ALDH1A1 P00352 2/20 0.43
HIF1A Q16665 1/20 0.42
MET P08581 1/20 0.41
TRPV1 Q8NER1 1/20 0.40
EPHX2 P34913 2/20 0.39
NR1H4 Q96RI1 1/20 0.39
HTT P42858 1/20 0.39
NAMPT P43490 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4767724 0.89 L3MBTL1 (0.41) HPGDKMT2AL3MBTL1ALDH1A1HIF1A
SCHEMBL4777516 0.89 L3MBTL1 (0.41) KMT2AL3MBTL1ALDH1A1HIF1ATRPV1
SCHEMBL4777299 0.88 L3MBTL1 (0.46) HPGDKMT2AMAPTL3MBTL1ALDH1A1
SCHEMBL4773304 0.88 ALDH1A1 (0.44) HPGDKMT2AMAPTL3MBTL1ALDH1A1
SCHEMBL4769612 0.88 HDAC6 (0.42) KMT2AL3MBTL1ALDH1A1HIF1ATRPV1
SCHEMBL4768057 0.87 L3MBTL1 (0.43) KMT2AL3MBTL1ALDH1A1HIF1ATRPV1
SCHEMBL4773557 0.87 L3MBTL1 (0.43) KMT2AMEN1L3MBTL1ALDH1A1HIF1A
SCHEMBL4777421 0.87 L3MBTL1 (0.43) KMT2AMEN1L3MBTL1ALDH1A1HIF1A
SCHEMBL4773260 0.86 L3MBTL1 (0.44) KMT2AL3MBTL1ALDH1A1HIF1ATRPV1
SCHEMBL4767750 0.86 HDAC6 (0.44) KMT2AL3MBTL1ALDH1A1HIF1AEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP claimed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US claimed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO claimed
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP disclosed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US disclosed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135435-A1 Certain chemical entities, compositions, and methods KIF5B, KIF2C, PLK1 HPGD 2681/4885KMT2A 1501/4885MEN1 1302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.